Yadav Sunny, Shekhawat Mamta, Jahagirdar Devashree, Kumar Sharma Nilesh
Cancer and Translational Research Lab, Dr. D.Y Patil Biotechnology & Bioinformatics Institute, Dr. D. Y. Patil Vidyapeeth, Pune 411033, Maharashtra, India.
Cancer Biol Med. 2017 Aug;14(3):242-253. doi: 10.20892/j.issn.2095-3941.2017.0038.
Since the failure of traditional therapy, gene therapy using functional DNA sequence and small RNA/DNA molecules (oligonucleotide) has become a promising avenue for cancer treatment. The discovery of RNA molecules has impelled researchers to investigate small regulatory RNA from various natural and artificial sources and determine a cogent target for controlling tumor progression. Small regulatory RNAs are used for therapeutic silencing of oncogenes and aberrant DNA repair response genes. Despite their advantages, therapies based on small RNAs exhibit limitations in terms of stability of therapeutic drugs, precision-based delivery in tissues, precision-based intercellular and intracellular targeting, and tumor heterogeneity-based responses. In this study, we summarize the potential and drawbacks of small RNAs in nucleic acid therapeutics for cancer.
由于传统疗法的失败，使用功能性DNA序列和小RNA/DNA分子（寡核苷酸）的基因疗法已成为一种有前景的癌症治疗途径。RNA分子的发现促使研究人员研究来自各种天然和人工来源的小调节RNA，并确定控制肿瘤进展的有力靶点。小调节RNA用于癌基因和异常DNA修复反应基因的治疗性沉默。尽管它们具有优势，但基于小RNA的疗法在治疗药物的稳定性、组织中的精准递送、细胞间和细胞内的精准靶向以及基于肿瘤异质性的反应方面存在局限性。在本研究中，我们总结了小RNA在癌症核酸治疗中的潜力和缺点。
